Smart investors know that long-term wealth isn't built on hype — it is built by owning quality businesses with real earnings power, global opportunity, and the ability to compound growth over time.
Right now, a handful of ASX 200 shares are quietly delivering just that and analysts think they could be top buys.
With that in mind, here are three ASX 200 shares that smart investors may want to have on their radar.
James Hardie Industries plc (ASX: JHX)
This ASX 200 share has long been a favourite of investors looking for exposure to the US housing and renovation market — and for good reason. James Hardie is a global leader in fibre cement and building solutions, with strong brand recognition and a footprint that spans North America, Europe, and the Asia Pacific.
Bell Potter thinks that now could be a great time to invest. It believes that "JHX is poised for continued earnings expansion, driven by the structural shift towards fibre cement in the US. Households in the US continue to shift to fibre cement cladding from vinyl/timber, providing a multi-year runway for JHX's revenue and profit growth."
In light of this, the broker has put a buy rating and $63.00 price target on its shares.
ResMed Inc. (ASX: RMD)
ResMed could be another ASX 200 share for smart investors to buy. It is the global leader in sleep apnoea treatment and respiratory care, with a growing digital health ecosystem that improves patient outcomes and drives recurring revenue.
Concerns about the impact of weight-loss drugs like GLP-1s have weighed on the share price in recent times, but ResMed continues to deliver earnings growth, expand its cloud-based software platform, and gain market share across key regions. In fact, the company believes they could be a positive and increase awareness and expand its addressable market.
Goldman Sachs is very positive on the company's outlook. So much so, it has a conviction buy rating and $49.30 price target on ResMed's shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix isn't yet a household name — but it could be soon. This clinical-stage biotech has emerged as one of the most promising players in the radiopharmaceuticals space, developing targeted therapies and diagnostics for cancer treatment.
Its lead product, Illuccix, is already approved and generating revenue in prostate cancer imaging, and the company has a growing pipeline of next-generation treatments.
While still early-stage compared to big pharma, Telix is executing commercially and scientifically, making it one of the most exciting growth stories on the Australian share market.
It is for this reason that Bell Potter has a buy rating and $34.00 price target on its shares.
